PCSK9 Inhibitor improves outcomes for patients with peripheral artery disease

LDL-cholesterol-lowering drug evolocumab reduced risk of major cardiovascular events and major adverse limb events among peripheral artery disease sub-population from the FOURIER trial. A new sub-analysis of the FOURIER clinical trial, however, now offers information on the safety and effectiveness of giving the PCSK9 inhibitor evolocumab on top of statin therapy to patients with peripheral artery disease.